[go: up one dir, main page]

AR120867A1 - Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina - Google Patents

Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina

Info

Publication number
AR120867A1
AR120867A1 ARP200103605A ARP200103605A AR120867A1 AR 120867 A1 AR120867 A1 AR 120867A1 AR P200103605 A ARP200103605 A AR P200103605A AR P200103605 A ARP200103605 A AR P200103605A AR 120867 A1 AR120867 A1 AR 120867A1
Authority
AR
Argentina
Prior art keywords
liver diseases
integrine
inhibitors
combined treatment
therapeutic agent
Prior art date
Application number
ARP200103605A
Other languages
English (en)
Inventor
Kraig Anderson
Christopher Bailey
Avirup Bose
Jacob Cha
Nicole Cooper
Darren Finkelstein
Linda Greenbaum
Johannes Hull
Susan Kirkland
Katerina Leftheris
Maureen Reily
Peter Tarsa
Chinweike Ukomadu
Original Assignee
Novartis Ag
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Pliant Therapeutics Inc filed Critical Novartis Ag
Publication of AR120867A1 publication Critical patent/AR120867A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente es una combinación farmacéutica que incluye un inhibidor de integrina aVb₁ y por lo menos un agente terapéutico adicional para la prevención, retardo o tratamiento de enfermedades o trastornos hepáticos. El agente terapéutico adicional puede ser un inhibidor del SGLT1/2, entre una diversa selección de agentes. Por ejemplo, la combinación farmacéutica incluye el ácido (S)-2-(4-metiltetrahidro-2H-piran-4-carboxamido)-9-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)nonanoico (Compuesto 1) y por lo menos un agente terapéutico adicional.
ARP200103605A 2019-12-20 2020-12-21 Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina AR120867A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962951600P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
AR120867A1 true AR120867A1 (es) 2022-03-23

Family

ID=74186952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103605A AR120867A1 (es) 2019-12-20 2020-12-21 Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina

Country Status (11)

Country Link
US (1) US20230060422A1 (es)
EP (1) EP4076454A1 (es)
JP (1) JP2023507364A (es)
KR (1) KR20220119424A (es)
CN (1) CN114929218A (es)
AR (1) AR120867A1 (es)
AU (1) AU2020408067B2 (es)
CA (1) CA3164941A1 (es)
IL (1) IL293894A (es)
TW (1) TW202135811A (es)
WO (1) WO2021127466A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4259647A4 (en) 2021-09-15 2025-03-26 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
KR20160132111A (ko) 2014-03-13 2016-11-16 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Fxr 작용제와 제조방법 및 용도
MY192927A (en) 2014-11-21 2022-09-15 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3237419B1 (en) 2014-12-22 2021-02-17 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CN107614526A (zh) 2015-06-05 2018-01-19 诺华股份有限公司 靶向骨形成蛋白9(bmp9)的抗体及其方法
CN115043944B (zh) 2015-08-03 2024-08-20 诺华股份有限公司 治疗fgf21相关病症的方法
WO2017078928A1 (en) 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
CN108779077A (zh) * 2015-12-30 2018-11-09 圣路易斯大学 作为pan整合素拮抗剂的间位氮杂环氨基苯甲酸衍生物
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017128896A1 (zh) 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
WO2017143134A1 (en) 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
US10183872B2 (en) 2016-06-13 2019-01-22 Qi Wang Counter circulating liquid processing system by repeatedly re-using thermal energy
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
TW201823208A (zh) * 2016-09-07 2018-07-01 美商普萊恩醫療公司 N－醯基胺基酸化合物及其使用方法
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
JP2019537557A (ja) 2016-10-04 2019-12-26 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法
CN107973790A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
ES3026786T3 (en) * 2017-01-11 2025-06-12 Kowa Co Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease
WO2018133730A1 (zh) 2017-01-20 2018-07-26 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
EP3580237B1 (en) 2017-02-08 2025-05-14 Novartis AG Fgf21 mimetic antibodies and uses thereof
WO2018190643A1 (en) 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
WO2018214959A1 (zh) 2017-05-26 2018-11-29 南京明德新药研发股份有限公司 作为fxr受体激动剂的内酰胺类化合物
CA3066987A1 (en) * 2017-06-21 2018-12-27 Novartis Ag Licofligozin for the treatment of non-alcoholic steatohepatitis
AU2018298253B2 (en) 2017-07-06 2020-11-19 Xuanzhu Biopharmaceutical Co., Ltd. FXR receptor agonist
BR112020008893A2 (pt) * 2017-11-07 2020-10-13 Bristol-Myers Squibb Company derivados de pirrolopirazina como inibidores de alfa v integrina
MD3761980T2 (ro) * 2018-03-07 2024-09-30 Pliant Therapeutics Inc Compuși de aminoacid și metodele utilizare
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN109053751A (zh) 2018-08-30 2018-12-21 成都海博锐药业有限公司 具有螺环结构的fxr调节剂
TWI877263B (zh) * 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CA3165000A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Combination treatment of liver diseases using integrin inhibitors

Also Published As

Publication number Publication date
CA3164941A1 (en) 2021-06-24
TW202135811A (zh) 2021-10-01
JP2023507364A (ja) 2023-02-22
WO2021127466A1 (en) 2021-06-24
IL293894A (en) 2022-08-01
EP4076454A1 (en) 2022-10-26
AU2020408067A1 (en) 2022-06-30
CN114929218A (zh) 2022-08-19
US20230060422A1 (en) 2023-03-02
KR20220119424A (ko) 2022-08-29
AU2020408067B2 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
AR120867A1 (es) Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
NI202100009A (es) Métodos para reducir la necesidad de revascu
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2024000201A1 (es) Composiciones y métodos para la inhibición de ras
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
ES2497494T3 (es) Método de tratamiento y prevención del hiperparatiroidismo secundario
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
MX2024001203A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con moduladores metabolicos para usarse en tratar enfermedades del higado graso.
MX2024000349A (es) Compuestos y usos de los mismos.
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
MX2020009757A (es) Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
CO2019013047A2 (es) Composiciones sólidas para administración oral
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2022013081A (es) Compuestos para el tratamiento de sars.
CL2021001536A1 (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
MX2016016139A (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
CL2022000214A1 (es) Inhibidores de enzimas
CO2022014499A2 (es) Moduladores de nlrp3
CR20200522A (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure